Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Geron Corporation (NASDAQ: GERN)  concerning whether a series of statements by Geron Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 27, 2018, the company issued a press release stating that patients in the IMbark study had shown only 10% spleen response rate and 32% symptom response rate.  Furthermore, the company revealed that Janssen had terminated its partnership with the Geron for the development of imetelstat. 

On this news, NASDAQ: GERN fell from $6.23 to $2.31 on September 27, 2018.

Based in Menlo Park, California, and founded in 1990 Geron Corporation operates as a biopharmaceutical company.

If you purchased shares of Geron Corporation (NASDAQ: GERN) on or before September 27, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185